Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Bloor

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Alimentary Pharmacology & Therapeutics|May 16, 2006
Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndromeJ Tack, S J Middleton, M C Horne, et al.
Antiviral Therapy|June 10, 2000
HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohortV Miller, A Cozzi-Lepri, K Hertogs, et al.
AIDS (London, England)|September 21, 2000
Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samplesB A Larder, K Hertogs, S Bloor, et al.
Journal of Clinical Microbiology|April 3, 2001
High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patientsR W Shafer, K Hertogs, A R Zolopa, et al.
AIDS (London, England)|October 8, 1999
Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community settingP R Harrigan, K Hertogs, W Verbiest, et al.
Journal of Virology|September 1, 1996
Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative GroupB A Larder, A Kohli, S Bloor, et al.
AIDS (London, England)|July 14, 2000
Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samplesK Hertogs, S Bloor, S D Kemp, et al.
Journal of Clinical Microbiology|July 16, 1999
Performance of the Affymetrix GeneChip HIV PRT 440 platform for antiretroviral drug resistance genotyping of human immunodeficiency virus type 1 clades and viral isolates with length polymorphismsM Vahey, M E Nau, S Barrick, et al.
AIDS (London, England)|March 9, 2000
Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimenJ L Casado, K Hertogs, L Ruiz, et al.
The Journal of Infectious Diseases|June 2, 1998
Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failureV Miller, A Phillips, C Rottmann, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Alimentary Pharmacology & Therapeutics|May 16, 2006
Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndromeJ Tack, S J Middleton, M C Horne, et al.
Antiviral Therapy|June 10, 2000
HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohortV Miller, A Cozzi-Lepri, K Hertogs, et al.
AIDS (London, England)|September 21, 2000
Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samplesB A Larder, K Hertogs, S Bloor, et al.
Journal of Clinical Microbiology|April 3, 2001
High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patientsR W Shafer, K Hertogs, A R Zolopa, et al.
AIDS (London, England)|October 8, 1999
Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community settingP R Harrigan, K Hertogs, W Verbiest, et al.
Journal of Virology|September 1, 1996
Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative GroupB A Larder, A Kohli, S Bloor, et al.
AIDS (London, England)|July 14, 2000
Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samplesK Hertogs, S Bloor, S D Kemp, et al.
Journal of Clinical Microbiology|July 16, 1999
Performance of the Affymetrix GeneChip HIV PRT 440 platform for antiretroviral drug resistance genotyping of human immunodeficiency virus type 1 clades and viral isolates with length polymorphismsM Vahey, M E Nau, S Barrick, et al.
AIDS (London, England)|March 9, 2000
Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimenJ L Casado, K Hertogs, L Ruiz, et al.
The Journal of Infectious Diseases|June 2, 1998
Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failureV Miller, A Phillips, C Rottmann, et al.
Pageof 3